Aberdeen Group plc Buys 241,876 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Aberdeen Group plc grew its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 152.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 400,598 shares of the company’s stock after acquiring an additional 241,876 shares during the quarter. Aberdeen Group plc owned about 0.53% of Kiniksa Pharmaceuticals International worth $16,525,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Mariner LLC boosted its stake in Kiniksa Pharmaceuticals International by 5.8% during the 3rd quarter. Mariner LLC now owns 13,253 shares of the company’s stock valued at $515,000 after purchasing an additional 732 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Kiniksa Pharmaceuticals International by 4.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after purchasing an additional 771 shares during the last quarter. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter valued at $32,000. Finally, Nordea Investment Management AB boosted its stake in Kiniksa Pharmaceuticals International by 0.7% during the 3rd quarter. Nordea Investment Management AB now owns 131,074 shares of the company’s stock valued at $5,016,000 after purchasing an additional 914 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Barry D. Quart sold 12,528 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total value of $567,142.56. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at approximately $567,957.42. This trade represents a 49.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. This trade represents a 59.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 48,605 shares of company stock valued at $2,122,646. 53.48% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on KNSA. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Trading Up 1.5%

Shares of KNSA stock opened at $49.55 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.25 and a 12-month high of $50.03. The stock’s 50-day moving average price is $45.66 and its 200-day moving average price is $42.04. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of 66.96 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same period last year, the firm posted ($0.12) earnings per share. The company’s revenue for the quarter was up 65.0% compared to the same quarter last year. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.